New controlled nucleation resource center
SP Scientifc's ControLyo Central is a suite of online resources to help freeze dried parenterals manufacturers.
SP Scientific announces ControLyo Central, a new suite of online resources detailing how ControLyo Technology works and its benefits, as well as research publications and brochures. Central to the new resource center are a series of short video presentations assessing the implementation value of new freeze drying technologies to scientific cycle development, production environments, and for financial business impact to freeze dried parenterals manufacturers.
Using an animated video format, SP Scientific introduces the science of ControLyo Technology, the process of implementation, and its potential financial benefits to businesses through factors such as shorter cycle times, reduced waste, and improved product quality.
The video shows how staff at an illustrative pharmaceutical company are faced with slowed production due to lyophilization problems including variations in moisture levels, homogeneity and yield for a new injectable drug. The characters introduce ControLyo Technology and explain in simple terms how the technology affords precise control over the point of freezing during the lyophilization process - a critical factor affecting variability within a batch. Further they describe how ControLyo can reduce cycle time, virtually eliminate waste, improve product quality without requiring any formulation change and maintain sterility. Finally, the cost analysis demonstrates a typical 4-month payback on investment in ControLyo Technology in their production environment.
Additional videos within ControLyo Central include footage of traditional lyophilization versus ControLyo Technology, and 'in action' applications involving lyophilization in both vials and syringes. Visitors to the site will find research publications and supporting literature with Spatially modulated illumination (SMI) microscopy images to further understand this innovative freeze drying breakthrough and its impact on product quality and production efficiencies.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance